| Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial J Verweij, PG Casali, J Zalcberg, A LeCesne, P Reichardt, JY Blay, ... The Lancet 364 (9440), 1127-1134, 2004 | 1863 | 2004 |
| American Society of Clinical Oncology treatment of unresectable non–small-cell lung cancer guideline: Update 2003 DG Pfister, DH Johnson, CG Azzoli, W Sause, TJ Smith, S Baker Jr, J Olak, ... Journal of Clinical Oncology 22 (2), 330-353, 2004 | 1823 | 2004 |
| American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non–small-cell lung cancer CG Azzoli, S Baker Jr, S Temin, W Pao, T Aliff, J Brahmer, DH Johnson, ... Journal of clinical oncology 27 (36), 6251, 2009 | 913 | 2009 |
| Treatment of adrenocorticotropin-dependent Cushing’s syndrome: a consensus statement BMK Biller, AB Grossman, PM Stewart, S Melmed, X Bertagna, J Bertherat, ... The Journal of Clinical Endocrinology & Metabolism 93 (7), 2454-2462, 2008 | 890 | 2008 |
| CREBBP mutations in relapsed acute lymphoblastic leukaemia CG Mullighan, J Zhang, LH Kasper, S Lerach, D Payne-Turner, ... Nature 471 (7337), 235-239, 2011 | 554 | 2011 |
| The genomic landscape of hypodiploid acute lymphoblastic leukemia L Holmfeldt, L Wei, E Diaz-Flores, M Walsh, J Zhang, L Ding, ... Nature genetics 45 (3), 242-252, 2013 | 550 | 2013 |
| Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer American Society of Clinical Oncology Journal of Clinical Oncology 15, 2996-3018, 1997 | 482 | 1997 |
| Does inequality in self-assessed health predict inequality in survival by income? Evidence from Swedish data E Van Doorslaer, UG Gerdtham Social science & medicine 57 (9), 1621-1629, 2003 | 478* | 2003 |
| Systemic therapy for stage IV non–small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update GA Masters, S Temin, CG Azzoli, G Giaccone, S Baker Jr, JR Brahmer, ... Journal of Clinical Oncology 33 (30), 3488, 2015 | 426 | 2015 |
| Systemic therapy for stage IV non–small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update N Hanna, D Johnson, S Temin, S Baker Jr, J Brahmer, PM Ellis, ... Journal of Clinical Oncology, 2017 | 397 | 2017 |
| 2011 Focused update of 2009 American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non–small-cell lung cancer CG Azzoli, S Temin, G Giaccone Journal of oncology practice 8 (1), 63-66, 2012 | 389 | 2012 |
| An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors ML Amador, D Oppenheimer, S Perea, A Maitra, G Cusati, ... Cancer Research 64 (24), 9139-9143, 2004 | 303 | 2004 |
| Irinotecan pathway genotype analysis to predict pharmacokinetics RHJ Mathijssen, S Marsh, MO Karlsson, R Xie, SD Baker, J Verweij, ... Clinical cancer research 9 (9), 3246-3253, 2003 | 302 | 2003 |
| Homocysteine and Methylmalonic Acid: Markers to Predict and Avoid Toxicity from Pemetrexed Therapy 1 Supported by Eli Lilly and Company. 1 C Niyikiza, SD Baker, DE Seitz, JM Walling, K Nelson, JJ Rusthoven, ... Molecular cancer therapeutics 1 (7), 545-552, 2002 | 302 | 2002 |
| Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes J Li, M Zhao, P He, M Hidalgo, SD Baker Clinical Cancer Research 13 (12), 3731-3737, 2007 | 291 | 2007 |
| A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies J Gilbert, SD Baker, MK Bowling, L Grochow, WD Figg, Y Zabelina, ... Clinical Cancer Research 7 (8), 2292-2300, 2001 | 286 | 2001 |
| Role of body surface area in dosing of investigational anticancer agents in adults, 1991–2001 SD Baker, J Verweij, EK Rowinsky, RC Donehower, JHM Schellens, ... Journal of the National Cancer Institute 94 (24), 1883-1888, 2002 | 280 | 2002 |
| Pharmacogenetics of ABCG2 and adverse reactions to gefitinib G Cusatis, V Gregorc, J Li, A Spreafico, RG Ingersoll, J Verweij, ... Journal of the National Cancer Institute 98 (23), 1739-1742, 2006 | 254 | 2006 |
| Incomplete stent apposition after implantation of paclitaxel-eluting stents or bare metal stents: insights from the randomized TAXUS II trial K Tanabe, PW Serruys, M Degertekin, E Grube, G Guagliumi, W Urbaszek, ... Circulation 111 (7), 900-905, 2005 | 252 | 2005 |
| Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer SD Baker, M Wirth, P Statkevich, P Reidenberg, K Alton, SE Sartorius, ... Clinical Cancer Research 5 (2), 309-317, 1999 | 242 | 1999 |
Alex SparreboomProfessor and Lucius A. Wing Chair, The Ohio State UniversityVerified email at osu.edu
